Chris Verslype

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

David Cunningham, Yves Humblet, Salvatore Siena et al. · New England Journal of Medicine · 2004 · 5K citations · Full text

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Open-label Phase 2, Hepatology, Medicine +8

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Arndt Vogel, Andrés Cervantes, Ian Chau et al. · Annals of Oncology · 2018 · 1K citations

Hepatology, Medicine, Histopathology +9

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer

Eric Van Cutsem, Helgi van de Velde, Petr Karásek et al. · Journal of Clinical Oncology · 2004 · 772 citations · Full text